Maura Gasparetto, MD

Publications

• Effects of the aldehyde dehydrogenase inhibitor disulfiram on the plasma pharmacokinetics, metabolism, and toxicity of benzaldehyde dimethane sulfonate (NSC281612, DMS612, BEN) in mice. Parise RA, Beumer JH, Clausen DM, Rigatti LH, Ziegler JA, Gasparetto M, Smith CA, Eiseman JL. Cancer Chemother Pharmacol. 2013 Dec;72(6):1195-204. doi: 10.1007/s00280-013-2296-5. Epub 2013 Sep 24. PMID: 24061865 [PubMed - indexed for MEDLINE]
• Deletion of the RNA-editing enzyme ADAR1 causes regression of established chronic myelogenous leukemia in mice. Steinman RA, Yang Q, Gasparetto M, Robinson LJ, Liu X, Lenzner DE, Hou J, Smith C, Wang Q. Int J Cancer. 2013 Apr 15;132(8):1741-50. doi: 10.1002/ijc.27851. Epub 2012 Oct 17. PMID: 22987615 [PubMed - indexed for MEDLINE]
• Aldehyde dehydrogenases in acute myeloid leukemia Clay Smith, Maura Gasparetto, Keith Humphries, Daniel A. Pollyea, Vasilis Vasiliou, and Craig T. Jordan. Ann. N.Y. Acad. Sci.
• ALDH Genes and Reactive Aldehydes Play Important Roles in HSCs and Leukemia and May Be Exploited to Treat AML. Maura Gasparetto, Craig T. Jordan, Mohammad Minhajuddin, Daniel A Pollyea, Vasilis Vasilou, Philip Reigan, R. Keith Humphries and Clayton A. Smith. 55th ASH Annual Meeting and Exposition. Session: 661. Malignant Stem and Progenitor Cells: Poster II
• Smith C, Gasparetto M, Jordan C, Pollyea DA, Vasiliou V. The effects of alcohol and aldehyde dehydrogenases on disorders of hematopoiesis. Adv Exp Med Biol. 2015;815:349-59. PubMed PMID: 25427917
• Imren S, Heuser M, Gasparetto M, Beer PA, Norddahl GL, Xiang P, Chen L, Berg T, Rhyasen GW, Rosten P, Park G, Moon Y, Weng AP, Eaves CJ, Humphries RK. Modeling de novo leukemogenesis from human cord blood with MN1 and NUP98HOXD13. Blood. 2014 Dec 4;124(24):3608-12. PubMed PMID: 25339361
• Blood 2014; 124(21):2238
• Smith C, Gasparetto M, Jordan C, Pollyea DA, Vasiliou V. The effects of alcohol and aldehyde dehydrogenases on disorders of hematopoiesis. Adv Exp Med Biol. 2015;815:349-59. PubMed PMID: 25427917
• Gasparetto M, Smith CA. ALDHs in normal and malignant hematopoietic cells: Potential new avenues for treatment of AML and other blood cancers. Chem Biol Interact. 2017 Oct 1;276:46-51. PubMed PMID: 28645468
• Gasparetto M, Pei S, Minhajuddin M, Khan N, Pollyea DA, Myers JR, Ashton JM, Becker MW, Vasiliou V, Humphries KR, Jordan CT, Smith CA. Targeted therapy for a subset of acute myeloid leukemias that lack expression of aldehyde dehydrogenase 1A1. Haematologica. 2017 Jun;102(6):1054-1065. PubMed PMID: 28280079
• Matsumoto A, Arcaroli J, Chen Y, Gasparetto M, Neumeister V, Thompson DC, Singh S, Smith C, Messersmith W, Vasiliou V. Aldehyde dehydrogenase 1B1: a novel immunohistological marker for colorectal cancer. Br J Cancer. 2017 Nov 7;117(10):1537-1543. PubMed PMID: 28881356
• Ye H, Adane B, Khan N, Sullivan T, Minhajuddin M, Gasparetto M, Stevens B, Pei S, Balys M, Ashton JM, Klemm DJ, Woolthuis CM, Stranahan AW, Park CY, Jordan CT. Leukemic Stem Cells Evade Chemotherapy by Metabolic Adaptation to an Adipose Tissue Niche. Cell Stem Cell. 2016 Jul 7;19(1):23-37. PubMed PMID: 27374788
• Gasparetto, et al. Low ferroportin expression in AML is correlated with good risk cytogenetics, improved outcomes and increased sensitivity to chemotherapy. Leukemia Research. Submitted
• Adane, et al. The Hematopoietic Oxidase NOX2 supports the Function of Leukemic Stem Cells Through Transcriptional Networks Controlling Differentiation. Submitted
• Adane B, Ye H, Khan N, Pei S, Minhajuddin M, Stevens BM, Jones CL, D'Alessandro A, Reisz JA, Zaberezhnyy V, Gasparetto M, Ho TC, Kelly KK, Myers JR, Ashton JM, Siegenthaler J, Kume T, Campbell EL, Pollyea DA, Becker MW, Jordan CT. The Hematopoietic Oxidase NOX2 Regulates Self-Renewal of Leukemic Stem Cells. Cell Rep. 2019 Apr 2;27(1):238-254.e6. PubMed PMID: 30943405
• Gasparetto M, Pei S, Minhajuddin M, Stevens B, Smith CA, Seligman P. Low ferroportin expression in AML is correlated with good risk cytogenetics, improved outcomes and increased sensitivity to chemotherapy. Leuk Res. 2019 May;80:1-10. PubMed PMID: 30852438
• DOI: 10.1200/CCI.22.00030
• Mohd Minhajuddin, Amanda Winters, Haobin Ye, Shanshan Pei, Brett Stevens, Austin Gillen, Krysta Engel, Stephanie Gipson, Monica Ransom, Maria Amaya, Anagha Inguva, Maura Gasparetto, Mark Althoff, Regan Miller, Ian Shelton, Hunter Tolison, Anna Krug, Rachel Culp-Hill, Angelo D’Alessandro, Daniel W Sherbenou, Daniel A. Pollyea, Clayton Smith and Craig T Jordan. Lysosomal Acid Lipase A Modulates Leukemia Stem Cell Response to Venetoclax/Tyrosine Kinase Inhibitor Combination Therapy in Blast Phase Chronic Myeloid Leukemia. Submitted
• Islam N, Reuben JS, Dale J, Gutman J, McMahon CM, Amaya M, Goodman B, Toninato J, Gasparetto M, Stevens B, Pei S, Gillen A, Staggs S, Engel K, Davis S, Hull M, Burke E, Larchick L, Zane R, Weller G, Jordan C, Smith C. Machine Learning-Based Exploratory Clinical Decision Support for Newly Diagnosed Patients With Acute Myeloid Leukemia Treated With 7 3 Type Chemotherapy or Venetoclax/Azacitidine. JCO Clin Cancer Inform. 2022 Sep;6:e2200030. PubMed PMID: 36194842